-
Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III regulatory clinical study for its Category 1 product, GST-HG171/ritonavir, in mild/moderate COVID-19 patients has been unblinded and has successfully reached its primary endpoint. Design and Results of the StudyThe multi-center, randomized, double-blind, placebo-controlled study aimed…
-
Boehringer Ingelheim’s Spevigo on Track for Priority Review for GPP Flare Prevention in China
•
Germany-based Boehringer Ingelheim’s (BI) interleukin-36 receptor (IL-36R)-targeted orphan drug, Spevigo (spesolimab), in subcutaneous injection form, is poised for priority review status in China. This recognition from the Center for Drug Evaluation (CDE) is attributed to its potential use in preventing flares in generalized pustular psoriasis (GPP), following the molecule’s earlier…
-
Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China
•
Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has been approved to enter clinical trials for the treatment of cervical cancer in China. The molecule will be assessed in combination with platinum chemotherapy and with or without bevacizumab, as per the Chinese firm’s announcement.…
-
Pfizer to Establish Smart Medical Innovation Center in Hangzhou’s Qiantang District
•
US pharmaceutical giant Pfizer (NSE: PFIZER) has announced a plan to establish a smart medical innovation center in the Qiantang district of Hangzhou city in China. This initiative aims to bolster the Chinese medical industry’s digital innovation capabilities and contribute to the advancement of healthcare solutions in the region. Empowering…
-
Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide
•
Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for its fostroxacitabine bralpamide (fostrox) and its use in the treatment of liver cancer. The patent, which remains valid until 2035 with potential for extensions, is a significant milestone for Medivir, considering China’s large population of…
-
Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform
•
Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry and Commerce, aiming to leverage their respective advantageous resources to create a comprehensive medical service platform. The collaboration will provide a range of health services, including high-end medical care, cell health, early tumor screening, and…
-
Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has entered into a strategic partnership with compatriot firm Yoltech Therapeutics Co., Ltd. The collaboration aims to advance the development of gene editing products, mRNA drugs, and related services in both domestic and international markets. Focus…
-
Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor
•
Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit president, effective as of January 1, 2024. Horn will take over from Allan Gabor, who is set to retire on December 31, 2023. In his new role, Horn will be responsible for formulating Merck’s development…
